Antimycotic Ciclopirox Olamine in the Diabetic Environment Promotes Angiogenesis and Enhances Wound Healing
dc.contributor.author | Ko, Sae Hee | |
dc.contributor.author | Nauta, Allison | |
dc.contributor.author | Morrison, Shane D. | |
dc.contributor.author | Zhou, Hongyan | |
dc.contributor.author | Zimmermann, Andrew | |
dc.contributor.author | Gurtner, Geoffrey C. | |
dc.contributor.author | Ding, Sheng | |
dc.contributor.author | Longaker, Michael T. | |
dc.contributor.editor | McNeil, Paul L. | |
dc.date.accessioned | 2012-10-26T16:29:32Z | |
dc.date.available | 2012-10-26T16:29:32Z | |
dc.date.issued | 2011-11-18 | en_US |
dc.identifier.citation | PLoS One. 2011 Nov 18; 6(11):e27844 | en_US |
dc.identifier.issn | 1932-6203 | en_US |
dc.identifier.pmid | 22125629 | en_US |
dc.identifier.doi | 10.1371/journal.pone.0027844 | en_US |
dc.identifier.uri | http://hdl.handle.net/10675.2/685 | |
dc.description.abstract | Diabetic wounds remain a major medical challenge with often disappointing outcomes despite the best available care. An impaired response to tissue hypoxia and insufficient angiogenesis are major factors responsible for poor healing in diabetic wounds. Here we show that the antimycotic drug ciclopirox olamine (CPX) can induce therapeutic angiogenesis in diabetic wounds. Treatment with CPX in vitro led to upregulation of multiple angiogenic genes and increased availability of HIF-1α. Using an excisional wound splinting model in diabetic mice, we showed that serial topical treatment with CPX enhanced wound healing compared to vehicle control treatment, with significantly accelerated wound closure, increased angiogenesis, and increased dermal cellularity. These findings offer a promising new topical pharmacologic therapy for the treatment of diabetic wounds. | |
dc.rights | Ko et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | en_US |
dc.subject | Research Article | en_US |
dc.subject | Biology | en_US |
dc.subject | Anatomy and Physiology | en_US |
dc.subject | Endocrine System | en_US |
dc.subject | Diabetic Endocrinology | en_US |
dc.subject | Skin | en_US |
dc.subject | Skin Physiology | en_US |
dc.subject | Medicine | en_US |
dc.subject | Anatomy and Physiology | en_US |
dc.subject | Endocrine System | en_US |
dc.subject | Diabetic Endocrinology | en_US |
dc.subject | Skin | en_US |
dc.subject | Skin Physiology | en_US |
dc.subject | Dermatology | en_US |
dc.subject | Dermatologic and Cosmetic Surgery | en_US |
dc.subject | Endocrinology | en_US |
dc.subject | Diabetic Endocrinology | en_US |
dc.subject | Diabetes Mellitus Type 2 | en_US |
dc.subject | Surgery | en_US |
dc.subject | Dermatologic and Cosmetic Surgery | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Antifungal Agents | en_US |
dc.subject.mesh | Blotting, Western | en_US |
dc.subject.mesh | Cell Line | en_US |
dc.subject.mesh | Diabetes Mellitus | en_US |
dc.subject.mesh | Gene Expression Regulation | en_US |
dc.subject.mesh | Human Umbilical Vein Endothelial Cells | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Hypoxia-Inducible Factor 1, alpha Subunit | en_US |
dc.subject.mesh | Mice | en_US |
dc.subject.mesh | NIH 3T3 Cells | en_US |
dc.subject.mesh | Neovascularization, Physiologic | en_US |
dc.subject.mesh | Pyridones | en_US |
dc.subject.mesh | Reverse Transcriptase Polymerase Chain Reaction | en_US |
dc.subject.mesh | Skin | en_US |
dc.subject.mesh | Time Factors | en_US |
dc.subject.mesh | Vascular Endothelial Growth Factor A | en_US |
dc.subject.mesh | Wound Healing | en_US |
dc.title | Antimycotic Ciclopirox Olamine in the Diabetic Environment Promotes Angiogenesis and Enhances Wound Healing | en_US |
dc.type | Article | en_US |
dc.identifier.pmcid | PMC3220686 | en_US |
dc.contributor.corporatename | Department of Cellular Biology and Anatomy | |
dc.contributor.corporatename | College of Graduate Studies | |
refterms.dateFOA | 2019-04-10T00:32:25Z | |
html.description.abstract | Diabetic wounds remain a major medical challenge with often disappointing outcomes despite the best available care. An impaired response to tissue hypoxia and insufficient angiogenesis are major factors responsible for poor healing in diabetic wounds. Here we show that the antimycotic drug ciclopirox olamine (CPX) can induce therapeutic angiogenesis in diabetic wounds. Treatment with CPX in vitro led to upregulation of multiple angiogenic genes and increased availability of HIF-1α. Using an excisional wound splinting model in diabetic mice, we showed that serial topical treatment with CPX enhanced wound healing compared to vehicle control treatment, with significantly accelerated wound closure, increased angiogenesis, and increased dermal cellularity. These findings offer a promising new topical pharmacologic therapy for the treatment of diabetic wounds. |